Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

PHASE3CompletedINTERVENTIONAL

Enrollment

554

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Hay Fever

Interventions

BIOLOGICAL

Placebo solution

4 x 2 injections over 21 days

BIOLOGICAL

gpASIT+TM

4 x 2 injections over 21 days

Trial Locations (3)

University Hospital Ghent, Ghent

Clinica dell'Azienda Opsedaliera Luigi Sacco, Milan

Fundacion Jiménez Diaz, Madrid